Search

Your search keyword '"Duchemann B."' showing total 237 results

Search Constraints

Start Over You searched for: Author "Duchemann B." Remove constraint Author: "Duchemann B."
237 results on '"Duchemann B."'

Search Results

2. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

6. Populations particulières : impact de l’état général et des principales comorbidités et de leurs traitements sur la prise en charge thérapeutique locale des patients présentant un Cancer Bronchique Non à Petites Cellules

7. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

8. Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc

12. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

14. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

18. Sécurité et efficacité de la reprise de l’immunothérapie après un antécédent de pneumopathie interstitielle induite par l’immunothérapie

20. 995P Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study

22. 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease

24. 11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature

25. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

27. 1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients

29. LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]

30. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

31. Socioeconomic status of patients hospitalized for COVID-19 in the Greater Paris area

32. 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)

33. LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]

34. Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront [FP07.06]

35. 25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

36. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.

37. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC

38. Statut socio-économique des patients hospitalisés pour COVID-19 en région parisienne

39. 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

41. Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients

43. Rechallenge avec les inhibiteurs des points de contrôle immunitaires (ICPis) : issues cliniques dans une cohorte nationale française de patients atteints d’un cancer bronchique non à petites cellules (CBNPC)

44. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

45. MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients

46. P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)

47. MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC

48. Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)

49. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

50. Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)[P1.04-31]

Catalog

Books, media, physical & digital resources